These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 22823964

  • 1. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia.
    Pompilio A, Crocetta V, Scocchi M, Pomponio S, Di Vincenzo V, Mardirossian M, Gherardi G, Fiscarelli E, Dicuonzo G, Gennaro R, Di Bonaventura G.
    BMC Microbiol; 2012 Jul 23; 12():145. PubMed ID: 22823964
    [Abstract] [Full Text] [Related]

  • 2. Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients.
    Pompilio A, Scocchi M, Pomponio S, Guida F, Di Primio A, Fiscarelli E, Gennaro R, Di Bonaventura G.
    Peptides; 2011 Sep 23; 32(9):1807-14. PubMed ID: 21849157
    [Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections.
    Mardirossian M, Pompilio A, Crocetta V, De Nicola S, Guida F, Degasperi M, Gennaro R, Di Bonaventura G, Scocchi M.
    Amino Acids; 2016 Sep 23; 48(9):2253-60. PubMed ID: 27270571
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of levofloxacin against planktonic and biofilm Stenotrophomonas maltophilia lifestyles under conditions relevant to pulmonary infection in cystic fibrosis, and relationship with SmeDEF multidrug efflux pump expression.
    Pompilio A, Crocetta V, Verginelli F, Di Bonaventura G.
    FEMS Microbiol Lett; 2016 Jul 23; 363(14):. PubMed ID: 27242375
    [Abstract] [Full Text] [Related]

  • 5. Antibacterial Properties and Efficacy of LL-37 Fragment GF-17D3 and Scolopendin A2 Peptides Against Resistant Clinical Strains of Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii In Vitro and In Vivo Model Studies.
    Farzi N, Oloomi M, Bahramali G, Siadat SD, Bouzari S.
    Probiotics Antimicrob Proteins; 2024 Jun 23; 16(3):796-814. PubMed ID: 37148452
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G, McKevitt M, Elborn JS, Tunney MM.
    J Cyst Fibros; 2012 May 23; 11(3):163-72. PubMed ID: 22138067
    [Abstract] [Full Text] [Related]

  • 7. Searching for new strategies against biofilm infections: Colistin-AMP combinations against Pseudomonas aeruginosa and Staphylococcus aureus single- and double-species biofilms.
    Jorge P, Grzywacz D, Kamysz W, Lourenço A, Pereira MO.
    PLoS One; 2017 May 23; 12(3):e0174654. PubMed ID: 28355248
    [Abstract] [Full Text] [Related]

  • 8. Pseudomonas aeruginosa Increases the Sensitivity of Biofilm-Grown Staphylococcus aureus to Membrane-Targeting Antiseptics and Antibiotics.
    Orazi G, Ruoff KL, O'Toole GA.
    mBio; 2019 Jul 30; 10(4):. PubMed ID: 31363032
    [Abstract] [Full Text] [Related]

  • 9. Bacteriophages as potential antibiotic potentiators in cystic fibrosis: A new model to study the combination of antibiotics with a bacteriophage cocktail targeting dual species biofilms of Staphylococcus aureus and Pseudomonas aeruginosa.
    Wang Z, De Soir S, Glorieux A, Merabishvili M, Knoop C, De Vos D, Pirnay JP, Van Bambeke F.
    Int J Antimicrob Agents; 2024 Sep 30; 64(3):107276. PubMed ID: 39009289
    [Abstract] [Full Text] [Related]

  • 10. Intragenic Antimicrobial Peptide Hs02 Hampers the Proliferation of Single- and Dual-Species Biofilms of P. aeruginosa and S. aureus: A Promising Agent for Mitigation of Biofilm-Associated Infections.
    Bessa LJ, Manickchand JR, Eaton P, Leite JRSA, Brand GD, Gameiro P.
    Int J Mol Sci; 2019 Jul 23; 20(14):. PubMed ID: 31340580
    [Abstract] [Full Text] [Related]

  • 11. Pseudomonas aeruginosa Alters Staphylococcus aureus Sensitivity to Vancomycin in a Biofilm Model of Cystic Fibrosis Infection.
    Orazi G, O'Toole GA.
    mBio; 2017 Jul 18; 8(4):. PubMed ID: 28720732
    [Abstract] [Full Text] [Related]

  • 12. Antibacterial, anti-biofilm and in vivo activities of the antimicrobial peptides P5 and P6.2.
    Martínez M, Polizzotto A, Flores N, Semorile L, Maffía PC.
    Microb Pathog; 2020 Feb 18; 139():103886. PubMed ID: 31778756
    [Abstract] [Full Text] [Related]

  • 13. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.
    Ratjen A, Yau Y, Wettlaufer J, Matukas L, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V.
    Antimicrob Agents Chemother; 2015 Jan 18; 59(1):711-3. PubMed ID: 25348526
    [Abstract] [Full Text] [Related]

  • 14. Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa.
    Twomey KB, O'Connell OJ, McCarthy Y, Dow JM, O'Toole GA, Plant BJ, Ryan RP.
    ISME J; 2012 May 18; 6(5):939-50. PubMed ID: 22134647
    [Abstract] [Full Text] [Related]

  • 15. Antibacterial potential of Stenotrophomonas maltophilia complex cystic fibrosis isolates.
    Crisan CV, Pettis ML, Goldberg JB.
    mSphere; 2024 Jul 30; 9(7):e0033524. PubMed ID: 38980073
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial activity of synthetic cationic peptides and lipopeptides derived from human lactoferricin against Pseudomonas aeruginosa planktonic cultures and biofilms.
    Sánchez-Gómez S, Ferrer-Espada R, Stewart PS, Pitts B, Lohner K, Martínez de Tejada G.
    BMC Microbiol; 2015 Jul 07; 15():137. PubMed ID: 26149536
    [Abstract] [Full Text] [Related]

  • 17. Exposure to extremely low-frequency magnetic field affects biofilm formation by cystic fibrosis pathogens.
    Di Bonaventura G, Pompilio A, Crocetta V, De Nicola S, Barbaro F, Giuliani L, D'Emilia E, Fiscarelli E, Bellomo RG, Saggini R.
    Future Microbiol; 2014 Jul 07; 9(12):1303-17. PubMed ID: 25517897
    [Abstract] [Full Text] [Related]

  • 18. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M, Morosini MI, Köksal E, Oliver A, Ekkelenkamp M, Cantón R.
    Antimicrob Agents Chemother; 2018 Jan 07; 62(1):. PubMed ID: 29084746
    [Abstract] [Full Text] [Related]

  • 19. Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens.
    Payne JE, Dubois AV, Ingram RJ, Weldon S, Taggart CC, Elborn JS, Tunney MM.
    Int J Antimicrob Agents; 2017 Sep 07; 50(3):427-435. PubMed ID: 28666755
    [Abstract] [Full Text] [Related]

  • 20. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
    Law JP, Wood AJ, Friman VP.
    Microbiol Spectr; 2022 Dec 21; 10(6):e0184222. PubMed ID: 36453898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.